Isoflurane Piramal

Isoflurane, the active ingredient in Isoflurane Piramal, is an inhalational anesthetic presented as a solution for inhalation use. It provides rapid induction and maintenance of a reversible loss of consciousness and analgesia during surgical procedures, allowing controlled anesthesia for adult and pediatric patients. The agent is administered via a calibrated vaporizer integrated into the anesthesia machine, delivering precise concentrations to achieve the desired depth of anesthesia while preserving cardiovascular stability.

GNH USA supplies Isoflurane Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, surgical centres and clinics worldwide.

Isoflurane is an inhalational anesthetic used in the management of peri‑operative anesthesia. - Induction of general anesthesia: rapid onset of unconsciousness and analgesia to facilitate endotracheal intubation and surgical start. - Maintenance of general anesthesia: continuous delivery maintains a stable anesthetic plane, allowing controlled ventilation and hemodynamic stability during operations. - Procedural sedation: provides deep sedation for brief diagnostic or interventional procedures when a full general anesthetic is not required. - Emergency airway management: facilitates rapid sequence induction and airway control in emergency settings.

Isoflurane may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Airway irritation: coughing or breathlessness during induction. - Hypotension: transient drop in blood pressure due to vasodilation. - Nausea and vomiting: postoperative emesis. - Dry mouth: reduced salivation. - Headache: mild to moderate headache during recovery. - Drowsiness: excessive sleepiness post‑operatively. - Shivering: postoperative muscle tremors. - Hypoxia: transient low oxygen saturation during emergence. - Taste disturbance: metallic or unpleasant taste during inhalation.

Serious or Rare Side Effects: - Malignant hyperthermia: life‑threatening hypermetabolic crisis triggered in susceptible individuals. - Arrhythmias: cardiac rhythm disturbances, including ventricular ectopy. - Hepatotoxicity: rare liver enzyme elevation or injury. - Respiratory depression: severe reduction in ventilation requiring support. - Seizures: rare occurrence in predisposed patients.

When using Isoflurane, clinicians should observe specific precautions to ensure patient safety and drug integrity. - Patient assessment: evaluate cardiovascular and respiratory status before administration. - Monitoring: continuously monitor blood pressure, heart rate, oxygen saturation, and end‑tidal anesthetic concentration. - Contraindications: avoid use in patients with known malignant hyperthermia susceptibility. - Drug interactions: adjust dosage when combined with other central nervous system depressants. - Environmental safety: ensure proper scavenging systems to limit occupational exposure. - Store at ambient temperature: keep the solution in original container, protect from light and moisture, and store below 25 °C.

Isoflurane can interact with other agents, influencing anesthetic depth or patient physiology.

Major Interactions (Avoid): - Potent CYP2E1 inducers (e.g., rifampin, carbamazepine): may increase hepatic metabolism of isoflurane, leading to a reduced anesthetic effect and the need for higher vaporizer settings. - Chronic alcohol consumption: can alter isoflurane pharmacodynamics, potentially increasing hepatic stress and modifying the required anesthetic concentration. - Neuromuscular blocking agents (e.g., rocuronium, vecuronium): may potentiate muscle relaxation when combined with isoflurane, necessitating careful dose titration to avoid prolonged paralysis.

Moderate Interactions (Monitor Closely): - Co‑administration with other inhalational anesthetics (e.g., sevoflurane, desflurane): additive central nervous system depression may require lower combined concentrations to maintain appropriate depth. - Opioids (e.g., fentanyl, morphine): synergistic analgesic effects can enhance respiratory depression, so ventilation parameters should be closely observed. - Beta‑blockers (e.g., propranolol, metoprolol): may exaggerate the hypotensive response produced by isoflurane, warranting vigilant blood pressure monitoring.